17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

US6903102B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Timothy J. Guzi · Chatham, US
• Kamil Paruch · Garwood, US
• Alan K. Mallams · Hackettstown, US
• Jocelyn Rivera · Monmouth Junction, US
• Ronald J. Doll · Maplewood, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Jonathan A. Pachter · Setauket, US
• Yi Liu · San Diego, US
• Anil K. Saksena · Upper Montclair, US

Key dates

• Filing date: Sep 5, 2002
• Grant date: Jun 7, 2005
• Expiry date: Feb 13, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.